Tigecycline in critical care

Crit Care Clin. 2008 Apr;24(2):365-75, x. doi: 10.1016/j.ccc.2007.12.007.


The emergence and spread of multidrug resistance in many pathogenic bacterial species is increasing at an alarming rate, especially with hospital-acquired infections in the critical care setting. Deaths associated with hospital-acquired infections have exceeded the number attributable to several of the top 10 leading causes of death reported in the United States. The emerging resistance limits the use of older antibiotics. Tigecycline is a new agent, and this article explores its role in the treatment of adults in the critical care setting.

Publication types

  • Review

MeSH terms

  • Adult
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Costs and Cost Analysis
  • Critical Care*
  • Cross Infection / drug therapy*
  • Cross Infection / epidemiology
  • Cross Infection / mortality
  • Humans
  • Microbial Sensitivity Tests
  • Minocycline / analogs & derivatives*
  • Minocycline / pharmacokinetics
  • Minocycline / pharmacology
  • Minocycline / therapeutic use
  • Randomized Controlled Trials as Topic
  • Tigecycline
  • United States / epidemiology


  • Anti-Bacterial Agents
  • Tigecycline
  • Minocycline